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ABSTRACT
ADVANCES IN TUMOR-TARGETED THERAPY USING NANOMEDICINE

Divya Karukonda
July 31st, 2017

Despite continuous improvement and significant progress made in
diagnostic and therapeutic approaches for cancer, it is still the leading cause of
death worldwide. Although conventional chemotherapy has made significant
advances in improving patient survival the indiscriminate destruction of normal
cells leads to severe side effects and poor clinical outcomes. Thus, there is a
need for effective delivery of drugs to the tumor site avoiding normal tissues to
reduce toxicity in the rest of the body. For this reason, a novel multidisciplinary
field called Nanotechnology has evolved in recent years and advances in this
field have contributed to the development of nanoscale materials to overcome
the lack of specificity of conventional chemotherapeutic agents for optimized
cancer therapy. Nanoparticles can be designed to preferentially target the tumor
site and deliver high drug payloads by either passive or active targeting. Passive
targeting exploits the preferential drug accumulation in tumor cells through
enhanced permeability and retention (EPR) effect. On the other hand, active

v

targeting uses functionalized nanoparticles to carry a drug to the specific site.
This targeting strategy is becoming a new standard in cancer treatment. A
selective and tumor site-specific treatment can be achieved by using various
ligands such as aptamers, antibodies, peptides, and small molecules. Targeting
nanocarriers serve as a highly promising strategy for effective cancer treatment,
as shown by encouraging results in many recent studies. This thesis highlights
the diversity of nanoparticle types, targeting mechanisms and active targeting
strategies. I will also discuss an emerging field of nano drug delivery using
biological nanovesicles called exosomes. Finally, I will discuss the current clinical
status of nanoparticle formulations.
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CHAPTER I
INTRODUCTION
Cancer and therapy
Cancer is the leading cause of death worldwide despite continuous
improvement in the therapeutic strategies and early detection. Cancer incidence
has been increasing in recent decades and American Cancer Society estimates
that the number of new cases are projected to increase by 50% worldwide from
14 million in 2012 to 22 million by 2030. In 2017, 1,688,780 new cancer cases
and 600,920 cancer deaths are estimated to occur in the United States (1).
Cancer is a complex disease caused by uncontrolled growth and division of
abnormal cells due to gene mutations. As a result of mutational changes, cancer
cells exhibit certain characteristics including proliferation, resistance to signals
that inhibit their growth and resistance to apoptotic signals that cause cell death,
which make it difficult to treat the disease (2). Cancer cells interact with the
microenvironment

to

acquire

different

capabilities

during

the

multistep

development of a tumor particularly, overcome immune response for survival,
activate stromal cells to inappropriately promote angiogenesis, and invade
through tissues, and metastasize to distant organs induced by tumor
microenvironment components (3).
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Standard treatment for cancer includes combinations of surgery, radiation
and chemotherapy (chemo). Other treatment options include hormonal therapy
and targeted therapy (including immunotherapy such as monoclonal antibody
therapy). The choice of therapy depends upon the location, grade of the tumor
and the stage of the disease. Over the last decade a number of potent anticancer
drugs have been developed with various mechanisms of action such as blocking
nucleic acid biosynthesis, interfering with gene transcription, causing cell cycle
arrest, inducing apoptosis, and inhibiting angiogenesis (4).
Limitations of conventional therapy
Conventional chemotherapy that targets DNA is very effective and has
resulted in improved survival rates of cancer patients. However, it has several
limitations such as poor solubility, poor selectivity, non-specific drug distribution,
fast clearance rate, systemic toxicity, multi-drug resistance, cancer reoccurrence,
off- target effects along with severe side effects (5). These limitations pose a
significant challenge in the effective treatment of cancer. Most of the
chemotherapeutics in the market at present such as doxorubicin, paclitaxel, and
vincristine have less selectivity toward the target and are systemically distributed
without selective localization to site of tumor. Thus, higher doses are required to
achieve pharmacological levels at the target site and this leads to increased
toxicity to the normal tissues causing severe side effects. An example of this is
anthracycline drug causing cardiotoxicity, severe in some cases (6). In order to
avoid toxic side effects, chemo drugs are often given at lower doses, which are

2

less than the required doses resulting in subsequent failure of therapy
accompanied by development of drug resistance and metastatic disease.
Hence, eradication of cancer still remains a major problem due to its
heterogeneous nature and inability of chemotherapeutics to reach the tumor site
without damaging the normal healthy tissues.
Effective solution
Delivering drug to the disease site is a major hurdle for many of the
diseases including cancer. Because of the limitations noted above there has
been enormous interest in developing an innovative technologies that can deliver
drug at the target site. Over a century ago Paul Ehrlich introduced a concept of
“Magic Bullet” for targeted drug delivery (7). It has two entities: the first one is
that the drug should recognize the target and the second is that the drug should
provide therapeutic action at the targeted site. Cell- or tissue-specific targeting is
achieved by encapsulating a

drug and targeting moiety in an appropriate

pharmaceutical carrier which is the revised version of Ehrlich magic bullet (8).
Nanoparticles can be designed including all three entities and could be used as
both therapeutics and diagnostics. A number of studies show that most of the
limitations of conventional drugs can be overcome by nanotechnology and that
nanoparticles as carriers have huge potential to overcome the limitations of
chemotherapeutics (9, 10).
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Nanotechnology in cancer
Nanotechnology involves use of nanometer scale materials and systems
by controlling the matter on a level of atomic, molecular and supramolecular
scale. (11-14). The size of nanomaterials is around 10-100 nm and their unique
size is ideal for increased solubility, oral bioavailability, rate of dissolution,
surface area, high therapeutic loading and rapid onset of therapeutic action upon
intracellular uptake (15). In contrast, conventional drugs are rapidly cleared from
the body, reducing the amount of drug at the tumor site (16). Nanocarriers with
drugs incorporated increase the half-life of drugs in circulation, allowing a greater
amount of drug to reach the target site (11). Anticancer drugs in nano
formulations

exhibit

enhanced

therapeutic

index

due

to

improved

pharmacokinetics, tissue distribution, and enhanced accumulation or release of
the drug at the tumor site (17). The nano-sized particles exhibit more
extravasation and permeability into tumor tissues with leaky vasculature in
contrast to neo-vasculature of normal tissues, minimizing off-target toxicities, and
enhancing delivery to site of action. Their small size also facilitates oral, nasal,
ocular, and parenteral routes of drug administration. Thus, nanoparticle drug
delivery systems can serve as the successful tools to anticancer therapy.
A variety of nanostructures have been investigated such as synthetic
biodegradable polymers, lipids (liposomes), mesoporous silica nanoparticles
(MSNs), micelles, quantum dots, carbon nanotubes, and gold nanoparticles for
the treatment of cancer (18-22). A summary of their properties is presented in
Table (1) (23)
4

Liposomes, first discovered by Dr. Alec Bangham in 1961 (24), and are
extensively explored as the

nanocarriers for the targeted drug delivery. A

separate field of liposomal technology research was started by the approval of
first nano drug - DoxilR which is a big hit in the market. The

field of liposomal

literature is only focused on liposomes without the term nano until 2000.
Liposomes are closed vesicles surrounded by a lipid bi-layer membrane
composed of phospholipids. Their hydrophilic core can be used for the
entrapment and delivery of water-soluble drugs. These vesicles are uni- or mutilamellar and have a potential to carry both hydrophilic and lipophilic molecules
entrapped within the lipid bilayer. Availability of liposomes with diverse properties
makes them the most intelligent drug carrier systems available (25)
Polymeric micelles are nano-sized vectors that contain amphiphilic block
copolymers which assemble to form nanoscopic core-shelled colloidal structures
termed micelles. Their advantage is in trapping drugs physically within the
hydrophobic cores or linking drugs covalently to component molecules of the
micelle. Additionally, they proved to be an excellent novel drug delivery system
due to their high stability in physiological conditions, high loading capacity, and
high accumulation of drug at target site (26).
Dendrimers are a class of polymeric materials. First discovered in the
early 1980’s by Donald Tomalia and colleagues (27), these hyper-branched,
tree-like, structured polymeric molecules originate from the Greek word dendron,
meaning a tree. As the chains growing from the core molecule become longer
and more branched, they adopt a globular structure. Dendrimers become
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densely packed as they extend out to the periphery, forming a closed membranelike structure. Their sizes range between 1.9 nm and 4.4 nm, the smallest
nancoarriers so far developed. Dendrimer-drug interactions or drug loading in
dendrimers may be achieved by various approaches: simple encapsulation in the
interior of dendrimers (illustrated in Fig. 1) involves electrostatic interactions and
covalent conjugations to the surface of the dendrimers. They serve as an ideal
carrier for drug delivery due to several advantages, for example, they can be
modulated for target-specific drug delivery, have a defined molecular weight, are
of a small size, and have good entrapment efficiency , thus offering a good
surface for functionalization (28).
The general term nanoparticles (NPs), describes a wide range of nano
systems including organic polymeric NPs, composed of synthetic or natural
polymers or proteins (i.e, albumin), solid lipid nanoparticles comprising of
physiological lipids, as well as inorganic NPs such as semiconductor NPs, iron
oxide NPs, quantum dots and gold NPs (29)
Polymeric nanoparticles are widely investigated nanoparticles in clinical
trials, and received much attention after the initial work of Langer and Folkman in
1976 (30). Because of their biodegradability, biocompatibility, high drug loading,
stability and flexibility, polymeric nanoparticles are used for controlled release of
drug. They usually consist of a general core-shell structure and are also
subdivided into various categories according to their basic chemical and core
shell composition and their morphology, including nanocapsules (NCs) and
nanospheres (NSs). Nanocapsules are hollow spherically-shaped vesicular
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particles, where the drug is confined to a hollow core, usually composed of oil
droplets, which is surrounded by a polymeric shell or membrane (31).
Nanospheres are solid colloidal matrix systems, ideally uniform in their core-shell
polymer partition, where a drug is dispersed or dissolved in the polymer matrix
(32) (Fig. 1). Various synthetic and natural polymers currently being investigated
for the design and potential applications of nanoparticles are polyethylene glycol
(PEG), poly lactic acid (PLA) and poly D,L-lactide co-glycolide) (PLGA) and their
copolymers PEG-PLA, PEG-PGA, PLGA and PEG-PLGA; these nanocarriers are
the most widely investigated synthetic polymers for drug and gene delivery (3338).

7

Figure 1. Basic structure of nanoparticles used for cancer therapy entrapped
with drug (Source : With permission from Katayoun et al., 2015 Active-targeted
Nanotherapy as Smart Cancer Treatment ) (39).
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Table 1
Summary of characteristics and representative applications of various nano
systems

Nano
particle

Size(nm)

Carbonnanotubes

0.5-3

Applications

Ref

Drug, gene and
peptide delivery

(23)

Controlled drug
delivery

(28)

50-100

Phospholipid bilayered
vesicles, Biocompatible
and good entrapment
efficiency

Passive and active
drug delivery of
drugs, gene,
peptides and
others

(25)

10-100

Hydrophobic core
wrapped by single layer
of hydrophilic polymers,
high drug entrapment,
payload, biostability

Active and passive
drug delivery, cell
specific targeting

(26)

Dendrimers <10

Liposomes

Polymeric
micelles

Polymeric
NPs

Gold

Characteristic
properties
Cylindrical tube of
crystal carbon sheets,
Biocompatible
Highly branched
synthetic polymeric
structures,
low polydispersity,
Biocompatible

10-1000

Biodegradable,
Biocompatible,
complete protection of
drug

<100

Small size with large
surface area,
biocompatible

9

Site selective
delivery, excellent
carrier for
controlled and
sustained drug
delivery
Hyperthermia,
drug delivery,
diagnostic assay,
radiotherapy
enhancement

(23)

(40)

Despite the variety of nanomaterials designed for tumor targeting, only a
limited number of formulations are clinically approved (Table 4). Treatment
efficacy is often impeded by nonspecific drug distribution and lack of specificity to
the target tissue site. Ideally, enhancing drug accumulation at the site of tumor
will lower the systemic exposure and result in a more efficient and patient-friendly
treatment. Several drug-targeting strategies can be engaged to reach target
tissues. These include active and passive targeted drug delivery which are
described in Chapter II. Targeted delivery of anticancer agents is a rapidly
evolving and is a highly promising field of research.

Indeed, targeted drug

delivery potentially increases the local concentration of the fraction of the
systemically administered dose reaching the tumor site, minimizing toxicity to the
adjacent healthy cells. A particular focus has been the active targeting of nano
drug delivery systems for the treatment of cancer because of the discovery of
new molecular targets, a deep understanding of biology of cancer, and the failure
of conventional treatment. Together, these lead to the enormous interest in
developing tumor targeted nanomedicine for the development of novel drug
delivery systems.
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CHAPTER II
DRUG TARGETING MECHANISMS
The key to success in cancer treatment is the therapeutic concentration at
the tumor site. The concentration of therapeutic agent reaching the tumor tissue
should be precise after crossing and penetrating all the biological barriers in the
body. Once the drug is at the active site, it should selectively destroy the cancer
cells, avoiding healthy tissues to reduce adverse effects and toxicity. To achieve
these goals, nanoparticle drug delivery systems use the characteristics of the
disease tissue to target their payloads. The drug-loaded nanoparticles reach the
tumor site by two of the principal mechanisms: passive and active drug targeting.
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Figure 2. Passive and active targeting to enhance permeability and retention. ,
Nanoparticles

(NPs)

can

be

passively

extravasated

through

leaky

vascularization, allowing their accumulation at the tumor region (A). In this case,
drugs may be released in the extracellular matrix and then diffuse throughout the
tissue or tumor. Active targeting (B) can enhance the therapeutic efficacy of
drugs by increasing accumulation and cellular uptake of NPs through receptormediated endocytosis. (Source: With permission from Suwassa et al., A focus on
nanoparticles as drug delivery system) (41).
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Passive drug Targeting
Nanoparticles

drug

delivery

systems

use

pathophysiological

characteristics of the tumor vasculature through the enhanced permeability and
retention (EPR) effect. The EPR concept was originally described by Maeda et
al., 1986 and this theory is based on the characteristics of tumor vasculature of
leaky blood vessels and lack of lymphatic drainage (42). This allows the diffusion
of longer circulating nanoparticles to the tumor site, avoiding health tissues, and
thereby

being

selectively

site-specific

(43,

44).

Most

passive-targeting

nanoparticles are surface-coated with PEG for biocompatibility, e.g., SP1049C,
Genexol- PM, NK911 (45, 46) in early clinical trials for treating various types of
cancer.
However, high heterogeneity of the EPR effect in tumors which varies
from patient to patient and within same subject is a significant limitation to this
strategy (47). The determination of precise impact of the EPR effect on
nanoparticle accumulation in tumor tissues becomes difficult since a variety of
parameters including size, shape, and zeta potential of nanoparticles are
involved in this process. Only a small part of injected dose is accumulated in
target cancer tissues which becomes a significant restriction in passive drug
strategy (42). In view of these limitations of passive targeting a considerable
amount of work is done and focused on developing active drug-targeting
strategies.
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Active drug Targeting:
Active drug targeting is aimed at delivery of active drug selectively to the
tumor site. Active drug-delivery strategies comprise use of a targeting ligand or
moiety attached on the surface of nanocarrier, which recognizes and enables the
nanoparticle to bind to receptors (tumor-specific epitope) overexpressed on
tumor cells. These receptors serve as tumor markers which are either expressed
at lower levels or essentially not expressed on normal cells. The interaction
between ligand and receptor is affected by binding affinity and selectivity of the
targeting unit and by the targeted receptor’s capacity (48). Receptor levels
depend not only on synthesis and stability, but also on recycling rate after
receptor activation and internalization (49). Hence the binding affinity of the
targeting ligand and number of ligand units conjugated and decorated on the
surface are the important factors affecting targeting efficiency. To target the
nanoparticles effectively to the desired site it is essential to have sufficient
quantity of ligands/targeting moieties along with high affinity binding to cell
surface receptors (50). Therefore, the most important feature of the targeting
ligand is to induce receptor-mediated endocytosis causing the internalization of
the drug carrier into the desired tumor tissue specific intracellular site (51, 52).
Currently there are many approaches available for active targeting to
tumor cells. All the ligands that can be attached to the nanoparticles can serve
as targeting moieties. There are wide variety of tumor-targeting moieties
including small molecules, peptides, monoclonal antibodies, aptamers and
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nucleic acids which specifically recognize receptors overexpressed on tumor cell
surface which will be discussed in Chapter III.

Figure 3. Types of ligands decorated on surface of nanoparticles for tumor
targeting.
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CHAPTER III
TYPES OF LIGANDS FOR ACTIVE TARGETING
The identity and characteristics of the targeting ligands are extremely
important for circulation time, cellular uptake, affinity, and extravasation.
Targeting ligands can be broadly classified as proteins (mainly antibodies and
their fragments), nucleic acids (aptamers), or other small molecules (peptides,
vitamins, and carbohydrates).
Monoclonal Antibodies (mAb)
Targeting cancer with a mAb was described by Milstein in 1981 (53).
mAbs bind to a receptor on the cell surface to induce several antibody-based
anticancer mechanisms including antibody-dependent cellular cytotoxicity
(ADCC) and complement-dependent cellular toxicity (CDC) (54, 55). The
feasibility of antibody-based tissue-targeting has been clinically demonstrated
with 17 different mAbs approved by the US Food and Drug Administration (FDA)
(56). The mAb rituximab (Rituxan) was approved in 1997 for treatment of
patients with non-Hodgkin's lymphoma — a type of cancer that originates in
lymphocytes (57). A year later, Trastuzumab (Herceptin), an anti-HER2 mAb
that binds to ErbB2 receptors, was approved for the treatment of HER2+ breast
cancer (58). The first angiogenesis inhibitor for treating colorectal cancer,
Bevacizumab (Avastin), an anti-VEGF mAb that inhibits the growth of new blood
16

vessels, was approved in 2004 (59). Today, over 200 delivery systems based on
antibodies or their fragments are in preclinical and clinical trials (60). Recent
developments in the field of antibody engineering have resulted in the
production of antibodies that contain animal and human origins such as chimeric
mAbs, humanized mAbs (those with a greater human contribution), and
antibody fragments. However, there are several limitations to this approach
including immunogenicity, large size, and cost of mAb synthesis, rapid
clearance, and environmental factors. The use of antibody fragments like Fab
and single chain variable fragments reduce the immunogenicity by keeping high
antigen binding specificity (52).
Aptamers
Aptamers are another emerging class of targeting ligands which are short
single-stranded RNA or DNA sequences of oligonucleotides that can be
designed as targeting ligand capable of binding to target receptors on the
surface of cancer cells with high selectivity and affinity (61). They form unique
three-dimensional structures with high ligand binding specificity needed for
target affinity. They are small size (~15 KDa), less immunogenic when
compared to antibodies, and can be chemically synthesized. Several aptamers
have been developed to bind specifically to receptors on cancer cells, and can
be considered suitable for nanoparticle-aptamer conjugate therapy (62).
Docetaxel (Dtxl)-encapsulated nanoparticles with aptamer (targets the antigen
on the surface of prostate cancer cells) functionalized surface were delivered
with high selectivity and efficacy in vivo (63). Similarly, doxorubicin encapsulated
17

DOTAP nanoparticles functionalized with DNA-based aptamer demonstrated a
significant reduction in tumor growth in a tumor xenograft model (64). RNAbased aptamers have also been developed which can selectively bind to the T
cell factor 1 and beta catenin in colon cancer cells (65-67). Locked nucleic acidmodified aptamers (LNA) used in iron oxide saturated lactoferrin nanocarriers
demonstrated improved survival rate in colon cancer xenograft (68). RNA-A10
aptamer PMSA (prostate specific membrane antigen) has also been reported for
better therapeutic efficacy (69-71).
Protein/peptides
A variety of proteins/peptides have been investigated for tumor targeting.
Several endogenous proteins which bind specifically to cell surface receptors
have been used for targeting purposes (72). For example, transferrin, a protein
involved in transport of iron, binds specifically to transferrin receptors which are
overexpressed in variety of malignancies. Choi et al. showed that transferrin
decorated PEGylated gold nanoparticles accumulated specifically in cancer cells
avoiding nonspecific transport of nanoparticles to the healthy cells (73, 74).
Muthu et al. demonstrated the enhanced efficacy of transferrin-functionalized
vitamin E-based micellar nanosystems in MDA-MB 231 breast cancer cells (18).
Jain et al. showed that transferrin-based nanosystems improved the antitumor
activity against breast cancer cells (21). Krishna et al. developed a unique
transferrin receptor targeting using apotransferrin protein as drug carrier for
nanoparticles (75).
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In addition to proteins, various peptides have also been used as targeting
ligands, which are specific to the receptors overexpress on tumor cells. In order
to find the best suitable peptide for targeting ligand, several peptide phage
display libraries are available for identification of specific targeting ligands (76). A
tumor homing penta-peptide CREKA that recognizes fibrin-associated plasma
protein has been used as a targeting ligand on iron oxide nanoparticles and
liposomes (77). Also penta-peptide LFC-131, an antagonist for CXCR4, a
chemokine responsible for majority of inflammatory related cancers, has been
used as a targeting ligand on polymeric nanoparticles for targeting CXCR4
overexpressed in cancer cells (78). Peptides have also been reported for the
receptor proteins viz. interleukin 11 receptor α (IL-11Rα) and 78 KDa glucoseregulated protein (GRP78) in prostate and breast tumors (79-81). Among the
different peptides, RGD peptide is a commonly used targeting ligand, which
selectively binds to αvβ3, αvβ5 integrin (angiogenesis markers) overexpressed in
endothelial and smooth muscle cells of tumor blood vessels. In an earlier
investigation by Danhier et al. (2009) RGD-decorated paclitaxel-loaded
nanoparticles demonstrated significantly enhanced tumor growth inhibition and
prolonged animal survival (82). RGD-conjugated PLGA NPs have also shown
enhanced antitumor efficacy in vivo (83).
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Small molecules
Small molecules with molecular weight less than 500 Da are a promising
class of targeting ligands because of their small size, low cost of synthesis, and
high stability. Pomper et al. identified small hydrophilic molecules from ureabased PMSA inhibitors which specifically target PMSA receptor overexpressed
on the surface of prostate cancer cells (84). Chandran et al. developed
docetaxel-encapsulated PLA/PCL-based targeted nanoparticles using PMSA as
a targeting moiety (85). This moiety proved to be an efficient targeting ligand for
the uptake of nanoparticles by PMSA-overexpressing cells. This small molecule
is also used as a targeting ligand for the development of a novel polymeric
nanoparticle BIND-014, composed of biodegradable hydrophobic PLA polymeric
core and hydrophilic PEG. This is the first targeted- and controlled-release
polymeric nanoparticle to reach clinical phase I trials for cancer chemotherapy
(86).
Among the different targeting strategies, vitamins are another class of
molecules widely investigated for tumor targeting. The vitamins employed for
targeting include folate, vitamin B12, thiamine, and biotin. The principal
advantages associated with vitamins, particularly folic acid, include stability (both
on the shelf and in the body), relative cost (low), lack of toxicity and
immunogenicity, and wide flexibility for diverse chemical reactions (87). Folic acid
has been widely investigated as a ligand in targeted drug delivery (88-90). Folic
acid has high affinity for folate receptors which are over expressed in many types
of solid tumors such as ovarian, lung, uterine, breast, head and neck cancers
20

(91). Besides the different tumors, folate has also been used as targeting ligand
for delivery of many drug conjugates and delivery systems including liposomes,
polymeric NPS through folate receptor mediated endocytosis (92). Folic acidfunctionalized PLGA nanoparticles and deoxycholic acid-o-carboxymethylated
chitosan-folic acid micelles have shown enhanced efficacy of doxorubicin and
paclitaxel, respectively (93, 94).
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Table 2
Examples of targeting ligands used in anticancer nanoformulations

Targeting
ligand

Receptor

Nanoformulation

Indication

Ref

Folate

Folate
receptor

PLGA polymeric NPsDoxorubicin

Breast cancer

(93)

Folate

Folate
receptor

Breast cancer

(94)

Melanoma

(95)

Hepatocellular
carcinoma

(96)

Breast Cancer

(97)

Breast Cancer

(18)

Brian cancer

(21)

Hepatocellular
Carcinoma

(98)

Folate
RGD

Folate
receptor
αvβ3,αvβ5
integrin
receptors

Deoxy cholic acid-ocarboxymethylated
chitosan-folic acid
micelles- Paclitaxel
Chitoson polyplex
liposomes- Nucleic acid
RGD modified
liposomes-paclitaxel

Transferrin
receptor
Transferrin
receptor
EGFR
receptor

Lipid coated PLGA
Nps- Aromatase
inhibitor
Vit E TPGS micellesDoxirubicin
PLGA polymeric NPsMethotrexate
DSPE-PEG lipid
polymeric complex

EGFR

EGFR
receptor

Poly(lactic acid-co-llysine) nanoparticles

Hepatocellular
Carcinoma

(99)

Fibrin
associated
plasma
proteins

Clotted
Plasma
proteins of
tumor vessels

CREKA conjugated
liposomes-Doxirubicin

Breast Cancer

(77)

Aptamers

Tumor DNA

DOTAP LiposomesDoxirubicin

Breast Cancer

(100)

Aptamers

CD133

PEGYLATED PLGA
NPs

Hepatocellular
Carcinoma

(101)

Aptamers

EGFR
receptor

Triple function RNA
NPs

Triplenegative
Breast Cancer

(78)

Transferrin
Transferrin
Transferrin
EGFR

Transferrin
receptor
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Bioconjugation for surface-functionalization of nanocarriers
In spite of the availability of a wide variety of targeting ligands, surface
functionalization remains a challenge. The major requirement for surface
functionalization is the presence of a targeting ligand on the NPs surface until the
active load is delivered to the target site. To make the functionalization stable
over the NP surface, a conjugation strategy that covalently links the ligands over
the surface of the NPs by using simple chemistry was established (102, 103).
The selection of the appropriate conjugation strategy is an important step, as the
chemicals used for the conjugation may affect the targeting ligand during the
process of conjugation (104). The most commonly used covalent conjugation
approaches are through amide linkages, which link carboxyl group to amine
using carbodiimide chemistry. It occurs by activation of carboxylic group present
on the NP surface by EDC (1-ethyl-3-(3-dimethyl amino propyl) carbodiimide and
NHS (N-hydroxysuccinimide) forming reactive intermediate which couples with
amine groups present in targeting ligand.
The chemical conjugation approach has been reported by Kocbek et al. to
functionalize the PLGA NPs by using Mb as targeting ligand and by Acharya et
al. who developed the nanoparticle bioconjugate by using epidermal growth
factor (EGF) as A targeting ligand (105, 106). In addition to the use of carboxylic
and amino groups, thiol functional groups have also been reported to form
disulfide bonds for surface functionalization (107). Thiol group can react with
other thiol group to form disulfide bond and also react with maleimide group to
form thioether groups. Shaik et al. used the similar concept of forming disulfide
23

bond to conjugate anti-My9 antibody to stealth liposomes (107). Similarly, several
other reports also demonstrated disulfide bond formation as a conjugation
strategy between maleimide processing NPs and thiol-bearing ligands and vice
versa (83, 104, 108). The highly specific, non-covalent reaction between avidin
and biotin has been used to functionalize avidin containing liposomes with
biotinylated antibodies (109). Other reaction complexes with streptavidin and
neutravidin are also in public domain for conjugation (110). Although these noncovalent binding techniques are available, the immunogenic reactions due to the
source of avidin make this approach the second choice after covalent
conjugation (111).
‘Click’ chemistry is another interesting technique to conjugate targeting
moieties to NPs (112). The use of click reactions became prevalent because of
their high efficiency, specificity, ease of availability of reagents, low nonspecific
binding, and physiological stability as compared to traditional crosslinking
carbodiimide chemistry. Click chemistry is a single step reaction carried out
under mild conditions in aqueous solutions producing high yield of product. It
involves reaction between azide and alkyne under various conditions and the
major classes of

reactions involved are cooper-catalyzed

azide-alkyne

cycloaddition (CuAAC), Strain- promoted azide-alkyne click chemistry (SPAAC)
and Tetrazine-trans-cyclooctene (TCO) ligation (113, 114). Koo et al. have
reported the biorthogonal copper free click chemistry for tumor targeted delivery
of nanoparticles (115).
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Exosome-mediated drug delivery as an emerging nanomedicine approach
Exosomes are lipid bilayer biological nanoparticles secreted by all the
cells in the body, present in almost all the body fluids, and play an important role
in cell–to-cell communication (116-119). Exosomes are emerging as potential
drug delivery nano vehicle (Figure 4). Exosomes have the advantages of being
less immunogenic and showing better biological tolerability and cellular
internalization compared with synthetic NPs (118, 120-122). There is a growing
interest in exploiting these biological NPs for delivering chemotherapeutics and
genetic material to the tumor site. With this growing interest, surface
functionalization of exosomes for selective delivery of chemotherapeutics and
siRNAs to cancer cells have been reported (123-125). Exosomes isolated from
different sources and the different small molecules delivered are summarized in
Table 3.
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Figure 4. Diagram depicting the structure of exosome carrying lipid, DNA, RNA
and protein (Source: With permission from Munagala et al., 2016 Bovine milk
derived exosomes for drug delivery) (126).
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Table 3
Therapeutic applications of Exosomes as nanocarriers

Source

Cargo

Target cancer
type

Outcome

Bovine milk

Witheferin- A

Breast and
Lung cancer

Tumor growth
inhibition

(126)

Bovine milk

Celastrol

Lung cancer

Tumor growth
inhibition

(127)

Bovine milk

Paclitaxel

Lung cancer

Tumor growth
inhibition

(128)

Mouse Dendritic
cells

Doxorubicin

Breast cancer

Tumor growth
inhibition

(129)

Breast cancer
cells

Doxorubicin

Breast and
Ovarian cancer

Tumor growth
inhibition

(130)

Prostate cancer
cells

Paclitaxel

Prostate
cancer

Increased
cytotoxicity

(131)

Machrophage

Paclitaxel

Lung cancer

Tumor growth
inhibition

(132)

Mesenchymal
stem cells

mir-122

Hepatocellular
carcinoma

Tumor growth
inhibition

(133)

Mesenchymal
stem cells

mir-143

Osteosarcoma

Inhibition of
migration

(134)

Monocytic cell

c-Myc siRNA

Lymphoma

Induction of
apoptosis

(135)

HEK 293 cell

PlK-1 siRNA

Bladder cancer

Induction of
apoptosis

(136)
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Ref

The field of exosomes as NPs is rather young and its use as a nanocarrier
to deliver cytotoxic drugs and phytochemical compounds has recently been
explored with encouraging results (126, 127, 129, 130, 137-139). For example,
Tian et al., 2014 and Srivastava et al., 2016 reported enhanced efficacy of
doxorubicin exosomal formulations (129, 138). Moreover, some studies have
shown enhanced therapeutic efficacy of cytotoxic drugs and natural compounds
while encapsulating these compounds in exosomes (127, 130, 131, 137, 139).
Saari et al. showed that cytotoxic effect of paclitaxel to prostate cancer cells
increased when encapsulated in exosomes (131). Milk derived exosomes have
been reported to enhance therapeutic response of withaferin A (126) and
celestrol (127), as well as to enhance the stability and therapeutic response of
anthocyanidins (139) in various cancers. Zhuang et al. showed that the
exosomal formulations of curcumin inhibited LPS-induced inflammation in a
mouse model compared with free curcumin and reported their positive effects
against brain tumor when given through intranasal route (137).
Due to their high complexity and variable composition, the cell specificity
of these exosomes is not predictable, leading to non-specific targeting. Such offtarget effects can be minimized through active targeting by functionalizing
extracellular vesicles with targeting ligands. Exosomes are functionalized in
several ways by decorating with specific ligands to improve the targeting ability
(129, 140, 141). Folic acid-functionalized milk-derived exosomes were shown to
enhance the therapeutic efficacy of withaferin A against lung cancer in vitro and
in vivo (126). The peptide i-RGD, which is specific to the αvβ3 integrin receptor
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that overexpressed in cancer cells, has been reported to fuse to the exosomal
membrane proteins and lipids, i.e., Lamp2b and glycosylphosphatidylinositol
(142). Alvarez et al. showed siRNA delivery to mouse brain by functionalizing
exosomes with RVG peptide by fusing with Lamp2b exosomal membrane
protein. These RVG exosomes could bind to specific receptor overexpressed in
brain tumors. Tian et al. used the same mechanism to deliver doxorubicin to
breast cancer cells (129). Chemical conjugation techniques, similar to those
used for NPs, have also been used for the functionalization of exosomes (143).
Kooijmans

et

functionalization.

al.
In

reported
this

a

post

technique,

insertion
EGFR

technique

for

exosome

nanobody-conjugated

PEG

phospholipid micelles were mixed with extracellular vesicles derived from Neuro
2A cells (143). Click chemistry has also been used for making functionalized
exosomes (144).
Clinical status
To date only a handful of nanoformulations are FDA approved and
available

for clinical use.

Liposomal formulations like

Doxil R,

Myocet,

DaunoXome, Depocyt, polymeric nanoparticles such as AbraxaneR, and
polymeric micelles like Glenexol-PM are FDA approved. The majority of the FDAapproved nanomedicines were developed based on passive targeting which
utilizes the EPR effect, due to the leaky vasculature of the tumor. There are
certain functionalized nanoformulations which have been specifically designed to
undergo ligand-mediated targeting selective to tumor site. The clinical status of
novel nanoformulations has been summarized in Table 4.
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MCC-465 is a novel PEGylated liposomal formulation encapsulating
doxorubicin tagged with human monoclonal antibody fragment F(ab’) in Phase I
clinical trial against metastatic stomach cancer (145). Recently, a PEGylated
liposomal formulation of doxorubicin functionalized with F (ab’) fragment of
antibody cetuximab (C225) was approved for clinical use (146). Liposomal
formulation of oxaliplatin (SGT53) functionalized with single chain antibody
fragment (TfRscFv) as targeting ligand is in a Phase I of clinical trial (147).
Cyclodextrin-based nanoparticles (CALAA-01) is the first nanoformulation in
clinical trial for the siRNA delivery to tumor site (148). Heat-activated PEGylated
liposomes containing doxorubicin (Thermodox) is in Phase III clinical trial for
treating liver cancer (149). Similar to liposomal formulations, some polymeric
nanoparticles are at different stages of clinical trials. PEG-poly(aspartic acid)
polymeric nanoparticles like NK 105 and NK 911, and PEG-cyclodextrin
nanoparticles like CRLX101 are in phase I and phase II clinical trials (150).
Targeted-polymeric nanomedicines like BIND-014, PEGylated PL(G)A docetaxel
formulation has completed the phase I and is now in Phase II clinical trials (86).
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Table 4
Summary of nanoformulations in market and clinical development
Nano
Carrier
type

Product
Name

Doxil®
(Caelyx® in
EU)

Myocet®
DaunoXome
®

Liposo
mes

Formulation

PEGylated
liposome

NonPEGylated
liposome
NonPEGylated
liposome

Indication

Clinical
Status

Doxorubicin

Breast
cancer,
ovarian
cancer,
multiple
myeloma,
Kaposi’s
sarcoma

Approved

Doxorubicin

Breast
cancer

Approved

Daunorubici
n

Kaposi’s
sarcoma

Approved

Drug

DepoCyt®

NonPEGylated
liposome

Cytarabine

Lipoplatin

PEGylated
liposome

Cisplatin

S-CKD602

PEGylated
liposome

CKD-602

NL CPT-11

PEGylated
liposome

Irinotecan
(CPT-11)

CPX-1

Liposome

Irinotecan

LE-SN38

Liposome

SN-38

MBP-426

Tf-NGPEliposome

Oxaliplatin
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Lymphomat
us
meningitis,
leukaemia,
glioblastom
a
Various
malignancie
s
Various
malignancie
s
Glioma
Colorectal
cancer
Colorectal
cancer
Various
malignancie
s

Approved

Phase III

Phase I/II
Phase I
Phase II
Phase II
Phase II

MCC-465

Thermodox
™

CPX-351

SGT-53

Abraxane®
(ABI-007)

Polyme
ric
nanopa
rticles

Liposome

Doxorubicin

Doxorubicin
Cytarabine+
daunorubici
n

Transferrintargeted
DNA
P53 gene
plasmid
liposome
Albuminbound
Paclitaxel
nanoparticle
(nab)

BIND-014

PEG-PLGA
Docetaxel
nanoparticle

DocetaxelPNP

Polymeric
Docetaxel
nanoparticle

CRLX101

CALAA-01

Polyme
ric
micelles

Human
antibody
fragment
(GAH)PEGliposome
Heatactivated
PEGylated
liposome

GenexolPM®

NK911
NK105

Cyclodextri
n-PEG
nanoparticle
Cyclodextri
n-PEGtransferrinnanoparticle
PEG-PLA
micelle
PEG-PAA
micelle
PEG-PAA
micelle

Gastric
cancer

Liver
cancer,
breast
cancer
Acute
myeloid
leukaemia

Phase I

Phase III

Phase II

Various
solid
malignancie
s

Phase I

Breast
cancer

Approved

Various
solid
malignancie
s
Various
solid
malignancie
s

Phase I

Phase I

Camptothec Various
Phase II
in
malignancies
Anti-RRM2
siRNA

Paclitaxel

Doxorubicin
Paclitaxel
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Various solid
Phase I
malignancies
Breast
cancer, lung
cancer,
Approved
ovarian
cancer
Various solid
Phase III
malignancies
Gastric
Phase II
cancer

PEGNC-6004
polyglutami
(Nanoplain™
c acid
)
micelle
PEG-PGA
NK012
micelle
PSP1049C
glycoprotein
micelle
Polymeric
Paclical®
micelle
Polymeric
NC-4016
micelle
Oncaspar®
Polym
er-drug
conjug
PK1
ate
(FCE28068)
nanop
articles
DOX-OXD
(AD-70)

PEG-drug

HPMA-drug

Dextran

Cisplatin

Pancreatic
cancer

SN-38

Various solid
Phase II
malignancies

Doxorubicin

Various
Phase II
malignancies

Paclitaxel
Oxaliplatin

Phase II

Ovarian
Phase III
cancer
Various solid
Phase I
malignancies

Lasparaginas Leukaemia
Market
e
Breast
cancer, lung
Doxorubicin cancer,
Phase II
colorectal
cancer
Various
Doxorubicin
Phase I
malignancies
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CHAPTER IV
CONCLUSION
The rapid advances in the field of nanomedicine have created a new
trend and opened the doors for the development of different tools and strategies
for anticancer therapy. Nanoparticle drug formulations have the potential to
overcome the limitations of conventional chemotherapy by their ability to
selectively target cancer cells over healthy tissue. Properly designed
nanoparticles have the ability to accumulate in tumors either by passive or
active targeting and enhance the cytotoxic effects of antitumor agents. Several
nanoformulations of anticancer drugs are being evaluated in phase II/III clinical
trials while relatively few have been approved for clinical use. Nanotechnology
provides an opportunity to revisit and reformulate the drugs that have been
shelved due to poor oral bioavailability, lack of selectivity to the desired target,
or extreme toxicity. Biological nanoparticles, i.e., exosomes, provide another
promising avenue for delivery of small and macromolecules. Nevertheless, the
field of nanotechnology has the potential to shift the paradigm of treatment for
cancer with an ever- growing arsenal of non-targeted and targeted
nanomedicines.
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Future perspective
In spite of various advantages of NPs, efficient delivery of drugs has never
been completely achieved due to lack of ideal drug delivery system. The major
limitations being low biocompatibility and toxicity. Their characterization, cost,
scalability, inability to evade host immune system, limited circulation time and
safety issues still remain as a challenge (151). Exosomes seem to overcome
several of the limitations associated with the conventional nanoparticles. They
have ability to target tissues by utilizing the intrinsic mechanisms of extracellular
vesicles. Exosomes are biocompatible, potentially nontoxic, less immunogenic,
and provide desired long-term safety for therapeutic use. They have the natural
ability to carry nucleic acids and other therapeutic molecules cross membranes
that are difficult to cross such as the blood brain barrier (BBB). There are
several recent studies published which isolated exosomes from different
sources like biological fluids and cell culture media using variety of strategies
(129, 142, 152). However, they still suffer from biocompatibility and scalability
issues. Particularly cost–effective, mass-scale production, drug loading and
targeting strategies are limitations, which lessen the throughput of this field.
More recent development of milk exosomes seem to overcome many of these
limitations (126-128, 139). However, immune-compromised subcutaneous
xenograft mouse models used in these studies have some limitations as the
formulations are not being tested in tumor microenvironment.
Tumor growth is complex and heterogeneous microenvironment consist of
different immune cells. So it is crucial to develop nanoformulations that can
35

adapt to the microenvironment and improve the selective targeting to tumors.
Apart from few, most of the formulations have not yet been in clinic considering
this aspect. The studies need to be performed with more sophisticated
humanized mouse models (i.e., patient-derived tumor xenograft models) and
also in different immunocompetent animal models (such as spontaneous tumor
models,

carcinogen-mediated

tumor

models)

which

take

tumor

microenvironment into consideration. This will better match the system of human
disease and create a wide scope for clinical translatability.
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